Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL2352340 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL8518463 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL5384786 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL4953759 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL8601641 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL1921958 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL1925892 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL433597 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL717375 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL534555 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| CN-109563045-B | Pd (II) -catalysed enantioselective beta-methylene C (sp) 3 ) -H bond activation | 斯克里普斯研究学院 | 2022-08-23 | — | — | CN | disclosed |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| WO-2021042890-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF AS TRK KINASE INHIBITOR | 罗欣药业(上海)有限公司 | 2021-03-11 | — | — | WO | disclosed |
| EP-3760619-A1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3184112-B1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE | FUJIFILM CORP (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-111741948-A | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2020-10-02 | — | — | CN | disclosed |
| EP-0445299-A1 | INOSITOL DERIVATIVE AND PRODUCTION THEREOF | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-09-11 | — | — | EP | disclosed |
| EP-0431197-A1 | MYOINOSITOL DERIVATIVE AND METHOD OF PRODUCTION THEREOF, AND PHOSPHORYLATING AGENT AND ITS USE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-06-12 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| US-4935528-A | HERBICIDES | ISHIHARA SANGYO KAISHA LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| US-4822402-A | NONPHYTOTOXIC POSTEMERGENCE WEED CONTROL IN PADDY RICE FIELDS | ISHIHARA SANGYO KAISHA LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| CN-86103880-A | Contain herbicide of thiophene sulfonamide compounds and preparation method thereof | — | 1987-01-21 | — | — | CN | disclosed |
| US-4131746-A | (DL)-13-Substituted sulfinyl-prostaglandin-like compounds and methods of making | SYNTEX (USA) INC. (US) | 1978-12-26 | — | — | US | disclosed |
| US-4049697-A | (DL)-13-Substituted sulfinyl-prostaglandin-like compounds and methods of making | SYNTEX (U.S.A.) INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-4036864-A | Chemical process | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) | 1977-07-19 | — | — | US | disclosed |
| US-3970685-A | (DL)-13-Substituted sulfinyl-prostaglandin-like compounds | SYNTEX (U.S.A.) INC. (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | ESR1 1115/4885MEN1 3985/4885KMT2A 1904/4885 |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | ESR1 1115/4885MEN1 3985/4885KMT2A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.